Polyclonal Antibody to Beta-Site APP Cleaving Enzyme 2 (bACE2)
| Code | Size | Price |
|---|
| PAB812Hu01-20ul | 20ul | £84.00 |
Quantity:
| PAB812Hu01-100ul | 100ul | £155.00 |
Quantity:
| PAB812Hu01-200ul | 200ul | £208.00 |
Quantity:
| PAB812Hu01-1ml | 1ml | £475.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
AEPLC; ALP56; ASP1; ASP21; BAE2; CDA13; CEAP1; DRAP; Beta-Site APP Cleaving Enzyme 2; Aspartic-like protease 56 kDa; Aspartyl protease 1; Down region aspartic protease; Memapsin-1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Beta Secretase 2
Reactivity:
Mu;Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;
Immunohistochemistry: 5-30ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-30ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Beta-Site APP Cleaving Enzyme 2 (bACE2) | RPB812Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||